New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
05:29 EDTNVSNovartis reports issuance of CRL for RLX030 by FDA
Novartis announced that the FDA has issued a Complete Response Letter, or CRL, regarding the Biologics License Application, or BLA, for RLX030 for the treatment of acute heart failure, or AHF, stating that further evidence on the efficacy of RLX030 is required for a U.S. license to be granted. The RLX030 submission to the FDA included phase II and III efficacy and safety data from the clinical development program, including the pivotal phase III RELAX-AHF study. Novartis is continuing to expand the data supporting the efficacy of RLX030 in acute heart failure with an extensive global clinical program, including the RELAX-AHF-2 trial which will enroll over 6,300 patients.
News For NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
08:57 EDTNVSGlaxoSmithKline return of transaction net proceeds to be reduced to GBP1B
Subscribe for More Information
May 4, 2015
07:35 EDTNVSNewYorkBio to hold a conference
Subscribe for More Information
May 1, 2015
15:14 EDTNVSExpress Scripts in settlement pact related to alleged Novartis kickbacks
Accredo Health, a wholly-owned subsidiary of Express Scripts (ESRX), entered a settlement and dismissal agreement with United States Attorney for the Southern District of New York, Preet Bharara, related to Accredo's alleged involvement in Novartis's (NVS) alleged participation in a kickback scheme involving Exjade, according to a court filing. In settlement of the United States' claims against Accredo in this action, Accredo shall pay to the United States a sum just over $45M, according to the court filing. A recent filing with the SEC noted that a total of $60M was set aside by Express Scripts to resolve the allegations with the federal government and all 50 states and a company spokesman confirmed the settlement involves $60M, according to The Wall Street Journal. Reference Link
07:43 EDTNVSExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 27, 2015
10:30 EDTNVSNovartis says Phase III Arzerra study met primary endpoint
Subscribe for More Information
06:19 EDTNVSPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
09:52 EDTNVSEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
05:25 EDTNVSNovartis backs FY15 revenue guidance of growth in mid-single digits
Subscribe for More Information
05:22 EDTNVSNovartis reports Q1 Core EPS $1.33, consensus $1.10
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use